Nateglinide
Suppliers
Names
[ CAS No. ]:
105816-04-4
[ Name ]:
Nateglinide
[Synonym ]:
Glinate
Starsis
SDZ DJN 608
Starlix
(2R)-2-{[(trans-4-Isopropylcyclohexyl)carbonyl]amino}-3-phenylpropanoic acid
N-{[trans-4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine
(-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine
(2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid
DJN 608
Natelide
N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine
N-{[trans-4-(Propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanin
MFCD00875706
ay4166
Starlix DS
Fastic-d5
A-4166
Fastic
D-Phenylalanine, N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-
N-[(trans-4-Isopropylcyclohexyl)carbonyl]-D-phenylalanine
(-)-N-(trans-4-Isopropylcyclohexyl-1-carbonyl)-D-phenylalanine
Nateglinide
Chemical & Physical Properties
[ Density]:
1.1±0.1 g/cm3
[ Boiling Point ]:
527.6±39.0 °C at 760 mmHg
[ Melting Point ]:
137-141ºC
[ Molecular Formula ]:
C19H27NO3
[ Molecular Weight ]:
317.423
[ Flash Point ]:
272.9±27.1 °C
[ Exact Mass ]:
317.199097
[ PSA ]:
66.40000
[ LogP ]:
4.21
[ Vapour Pressure ]:
0.0±1.5 mmHg at 25°C
[ Index of Refraction ]:
1.536
[ Storage condition ]:
Room temp
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- SQ7318950
- CHEMICAL NAME :
- D-Phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-
- CAS REGISTRY NUMBER :
- 105816-04-4
- LAST UPDATED :
- 199806
- DATA ITEMS CITED :
- 7
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD - Lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Gastrointestinal - hypermotility, diarrhea
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S5,1997
- TYPE OF TEST :
- LD - Lethal dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- >2 gm/kg
- TOXIC EFFECTS :
- Gastrointestinal - nausea or vomiting
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S9,1997 ** OTHER MULTIPLE DOSE TOXICITY DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 90 gm/kg/13W-I
- TOXIC EFFECTS :
- Endocrine - changes in adrenal weight Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S13,1997
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 182 gm/kg/52W-I
- TOXIC EFFECTS :
- Gastrointestinal - changes in structure or function of salivary glands Gastrointestinal - ulceration or bleeding from stomach Nutritional and Gross Metabolic - weight loss or decreased weight gain
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S63,1997
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 27300 mg/kg/13W-I
- TOXIC EFFECTS :
- Gastrointestinal - changes in structure or function of salivary glands Liver - change in gall bladder structure or function Related to Chronic Data - death
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S35,1997
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 36400 mg/kg/52W-I
- TOXIC EFFECTS :
- Gastrointestinal - changes in structure or function of salivary glands
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S79,1997 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 27 gm/kg
- SEX/DURATION :
- female 17-22 day(s) after conception lactating female 1-21 day(s) post-birth
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
- REFERENCE :
- YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 25(Suppl 1),S139,1997
Safety Information
[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
[ Hazard Codes ]:
Xn: Harmful;
[ Risk Phrases ]:
R22
[ Safety Phrases ]:
24/25-36
[ RIDADR ]:
NONH for all modes of transport
[ RTECS ]:
SQ7318950
[ HS Code ]:
2924299090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2924299090
[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Articles
Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)
This study involves the design and characterization of Nateglinide (NAT) microspheres to enhance patient compliance. Ionic gelation technique was used to prepare Nateglinide Microspheres by using rate...
Health Policy 104(1) , 27-31, (2012)
In Germany, coverage decisions in the statutory health insurance (SHI) system are based on the principles of evidence-based medicine. Recently, an evidence assessment by the Institute for Quality and ...
Int. J. Clin. Pract. 59(10) , 1218-28, (2005)
Therapy for type 2 diabetes mellitus should aim to control not only fasting, but also postprandial glucose levels. Nateglinide, a d-phenylalanine derivative, restores postprandial early phase insulin ...